{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cyclical+Follow+Up&page=2", "query": { "intervention": "Cyclical Follow Up", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cyclical+Follow+Up&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T19:17:06.476Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03894540", "title": "Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "IPN60090", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "IPN60090 single administration", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2019-03-22", "completion_date": "2020-12-21", "has_results": true, "last_update_posted_date": "2022-09-13", "last_synced_at": "2026-09-26T19:17:06.476Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03894540" }, { "nct_id": "NCT06696768", "title": "Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Adenocarcinoma", "Stage III Colorectal Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Unresectable Colorectal Adenocarcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Emavusertib", "type": "BIOLOGICAL" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2025-06-23", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-09-26T19:17:06.476Z", "location_count": 13, "location_summary": "Gainesville, Florida • Shiloh, Illinois • Fairway, Kansas + 8 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Shiloh", "state": "Illinois" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06696768" }, { "nct_id": "NCT04863950", "title": "Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Lomustine", "type": "DRUG" }, { "name": "Imipramine Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 25, "start_date": "2022-05-25", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2025-08-27", "last_synced_at": "2026-09-26T19:17:06.476Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04863950" }, { "nct_id": "NCT06423326", "title": "Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Borderline Resectable Pancreatic Ductal Adenocarcinoma", "Resectable Pancreatic Adenocarcinoma", "Stage I Pancreatic Cancer AJCC v8", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Pancreatic Surgical Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2024-08-06", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-09-26T19:17:06.476Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06423326" }, { "nct_id": "NCT02169791", "title": "Nonmyeloablative Haploidentical Transplant Followed by MLN9708", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukemia", "Chronic Leukemia", "Myelodysplastic Syndrome", "Lymphomas", "Multiple Myeloma" ], "interventions": [ { "name": "MLN9708", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northside Hospital, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2014-07-15", "completion_date": "2020-07-28", "has_results": true, "last_update_posted_date": "2021-09-02", "last_synced_at": "2026-09-26T19:17:06.476Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02169791" }, { "nct_id": "NCT02766335", "title": "Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Recurrent Squamous Cell Lung Carcinoma", "Stage IV Squamous Cell Lung Carcinoma AJCC v7" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2014-07-31", "completion_date": "2020-09", "has_results": true, "last_update_posted_date": "2023-05-25", "last_synced_at": "2026-09-26T19:17:06.476Z", "location_count": 993, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 623 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02766335" }, { "nct_id": "NCT04666597", "title": "Pandemic-adapted Caries Care Multicentre Single-group Interventional Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Dental Caries in Children" ], "interventions": [ { "name": "Modified CariesCare International management", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Universidad El Bosque, Bogotá", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "3 Years", "maximum_age": "8 Years", "sex": "ALL", "summary": "3 Years to 8 Years" }, "enrollment_count": 409, "start_date": "2020-11-15", "completion_date": "2021-12-30", "has_results": false, "last_update_posted_date": "2023-12-04", "last_synced_at": "2026-09-26T19:17:06.476Z", "location_count": 2, "location_summary": "Indianapolis, Indiana • Boston, Massachusetts", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04666597" }, { "nct_id": "NCT04302025", "title": "A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" }, { "name": "Entrectinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Pralsetinib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "SBRT", "type": "DRUG" }, { "name": "Resection", "type": "PROCEDURE" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Divarasib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2020-11-06", "completion_date": "2030-05-30", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-09-26T19:17:06.476Z", "location_count": 38, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 28 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04302025" }, { "nct_id": "NCT06677190", "title": "Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Ovarian Carcinoma", "Endometrial Cancer", "Uterine Cancer", "Cervical Cancer", "Vulvar Cancer", "Gynecologic Cancer", "Vaginal Cancer" ], "interventions": [ { "name": "Belzutifan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 32, "start_date": "2024-12-20", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2025-11-05", "last_synced_at": "2026-09-26T19:17:06.476Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06677190" }, { "nct_id": "NCT02219659", "title": "Pilot Study on Pairing Sedation Strategies and Weaning", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Respiratory Failure" ], "interventions": [ { "name": "Sedation Protocol with Daily Interruption", "type": "DRUG" }, { "name": "Sedation Protocol Without Daily Interruption", "type": "DRUG" }, { "name": "Fentanyl Push First", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MemorialCare Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2014-12", "completion_date": "2018-05-18", "has_results": true, "last_update_posted_date": "2025-10-07", "last_synced_at": "2026-09-26T19:17:06.476Z", "location_count": 1, "location_summary": "Long Beach, California", "locations": [ { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02219659" } ] }